Global pharmaceutical company, Clinuvel (ASX:CUV) has today announced the expansion of its Singapore lab facilities.
The lab, owned by its Singaporean subsidiary, Vallaurix will incorporate a variety of critical analytical methodologies.
The expansion comes as part of the company's increase in research activities on next generation products and the supply chain integration of critical analytical functions.
The development will enable the Singaporean team to employ a number of analytical methodologies in-house to support new product development as well as quality control functions.
The company says with the expertise and template laid down by the work done for patients with the innovative drug SCENESSE it expects new molecules to go through the regulatory pathway much faster.